Tag Archives: Guy Chamberland

GrowPros

Tetra Bio-Pharma Receives Health Canada Approval for Phase 2 Cannabis Oil Trial in Partnership with Sante Cannabis

Tetra Bio-Pharma Receives Health Canada Approval for Phase 2 Cannabis Oil Trial in Partnership with Sante Cannabis

OTTAWA, Ontario, Jan. 29, 2018 /Weed Wire/ – Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, is pleased to announce the approval by Health Canada of a Phase 2 clinical trial designed to evaluate the safety and efficacy of different doses and ratios of medical cannabis oil (THC & CBD) to improve uncontrolled chronic pain in cancer and non-cancer patients.

GrowPros

Tetra Bio-Pharma Receives Approval from Health Canada of its Phase 1 Clinical Trial with PPP005 (Cannabis Oil)

OTTAWA, Ontario, Jan. 16, 2018 /Weed Wire/ – Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, is pleased to announce that it has received a No Objection Letter (NOL) from the Therapeutic Products Directorate (TPD), Health Canada to evaluate the safety, pharmacokinetics and pharmacodynamics of its cannabis oil PPP005.

GrowPros

Tetra Bio-Pharma Enters into Agreement to Acquire Remaining 20% Interest in Phytopain Pharma Subsidiary

OTTAWA, Ontario, Jan. 2, 2017 /Weed Wire/ — Tetra Bio-Pharma Inc. (“Tetra” or the “Corporation”) (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development, today announced that it has entered into a share purchase agreement (the “Purchase Agreement”) with entities controlled by André Rancourt, Chairman of the Board of Directors of the Corporation, and Guy Chamberland, Chief Scientific Officer of the Corporation (collectively, the “Vendors”).

GrowPros

Tetra Bio-Pharma Continues Forward into the Veterinary Ophthalmology Market by Entering into an Agreement with Drs. Cullen and Webb

OTTAWA, Ontario, Oct. 12, 2017 /Weed Wire/ – Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, today announced the addition of two members to its clinical advisory board for the veterinary market – Dr. Cheryl Cullen, an American Board-certified Veterinary Ophthalmologist, and Dr. Webb, an American Board of Veterinary Ophthalmology (ABVO) Resident.

Tetra Bio-Pharma Its Position

Tetra Bio-Pharma Strengthens its Position on Bringing Marijuana to Patients in a Form Acceptable to Health Care Professionals

OTTAWA, Ontario, July 5, 2017 /Weed Wire/ — Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (CSE:TBP)(CSE:TBP.CN)(CNSX:TBP)(OTCQB:TBPMF), today announced that it has strengthened its position on bringing marijuana to patients in the form of a prescription drug.

GrowProws

GrowPros Announces the Acquisition of Laboratoires Holizen Inc. and a $600,000 Non-Brokered Private Placement

OTTAWA, Ontario, June 22, 2016 /Weed Wire/ — GrowPros Cannabis Ventures Inc. (“GrowPros” or the “Company”) (CSE:GCI) is pleased to announce the acquisition of the assets of Laboratoires Holizen Inc. (“Holizen”) for $450,000.


Top